Literature DB >> 30467967

An overview of percutaneous coronary intervention in dialysis patients: Insights from a Japanese nationwide registry.

Yohei Numasawa1, Taku Inohara2,3, Hideki Ishii4, Kyohei Yamaji5, Keita Hirano6, Shun Kohsaka3, Mitsuaki Sawano3, Toshiki Kuno1, Masaki Kodaira1, Shiro Uemura7, Kazushige Kadota8, Tetsuya Amano9, Masato Nakamura10.   

Abstract

OBJECTIVES: This study sought to provide an overview of percutaneous coronary intervention (PCI) in dialysis patients from a Japanese nationwide registry.
BACKGROUND: Little is known about dialysis patients undergoing PCI because few are enrolled in clinical trials.
METHODS: We analyzed 624,900 PCI cases including 41,384 dialysis patients (6.6%) from 1,017 Japanese hospitals between 2014 and 2016. We investigated differences in characteristics and in-hospital outcomes between dialysis and nondialysis patients, and assessed factors associated with an increased risk of adverse outcomes.
RESULTS: Dialysis patients had more comorbidities than nondialysis patients and higher rates of complications including in-hospital mortality (3.3% vs. 1.5%, respectively, in the acute coronary syndrome [ACS] cohort, 0.2% vs. 0.1% in the non-ACS cohort) and bleeding complications requiring blood transfusion (1.1% vs. 0.4% in ACS, 0.5% vs. 0.2% in non-ACS). Dialysis was significantly associated with an increased risk of in-hospital mortality (odds ratio [OR]: 1.42, 95% confidence interval [CI]: 1.24-1.62 in ACS, OR: 2.25, 95% CI: 1.66-3.05 in non-ACS) and bleeding (OR: 1.60, 95% CI: 1.30-1.96 in ACS, OR: 1.55, 95% CI: 1.27-1.88 in non-ACS). For dialysis patients, age, acute heart failure, and cardiogenic shock were associated with an increased risk of in-hospital mortality in the ACS cohort, whereas age, female gender, and history of heart failure were associated with higher in-hospital mortality in the non-ACS cohort.
CONCLUSIONS: PCI was widely performed for dialysis patients with either ACS or non-ACS in Japan. Dialysis patients had a greater risk of adverse outcomes than nondialysis patients after PCI.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  chronic kidney disease; coronary artery disease; end-stage renal disease

Mesh:

Year:  2018        PMID: 30467967     DOI: 10.1002/ccd.27986

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

1.  Incidence and prognostic impact of the calcified nodule in coronary artery disease patients with end-stage renal disease on dialysis.

Authors:  Akihiko Okamura; Hiroyuki Okura; Saki Iwai; Azusa Sakagami; Daisuke Kamon; Yukihiro Hashimoto; Tomoya Ueda; Tsunenari Soeda; Makoto Watanabe; Yoshihiko Saito
Journal:  Heart Vessels       Date:  2022-04-30       Impact factor: 1.814

2.  Validation of Japanese Bleeding Risk Criteria in Patients After Percutaneous Coronary Intervention and Comparison With Contemporary Bleeding Risk Criteria.

Authors:  Takeshi Shimizu; Yuya Sakuma; Yuta Kurosawa; Yuuki Muto; Akihiko Sato; Satoshi Abe; Tomofumi Misaka; Masayoshi Oikawa; Akiomi Yoshihisa; Takayoshi Yamaki; Kazuhiko Nakazato; Takafumi Ishida; Yasuchika Takeishi
Journal:  Circ Rep       Date:  2022-04-16

3.  Contemporary use and trends in percutaneous coronary intervention in Japan: an outline of the J-PCI registry.

Authors:  Mitsuaki Sawano; Kyohei Yamaji; Shun Kohsaka; Taku Inohara; Yohei Numasawa; Hirohiko Ando; Osamu Iida; Toshiro Shinke; Hideki Ishii; Tetsuya Amano
Journal:  Cardiovasc Interv Ther       Date:  2020-05-21

4.  Association of the Hemoglobin to Serum Creatinine Ratio with In-Hospital Adverse Outcomes after Percutaneous Coronary Intervention among Non-Dialysis Patients: Insights from a Japanese Nationwide Registry (J-PCI Registry).

Authors:  Yohei Numasawa; Taku Inohara; Hideki Ishii; Kyohei Yamaji; Shun Kohsaka; Mitsuaki Sawano; Masaki Kodaira; Shiro Uemura; Kazushige Kadota; Tetsuya Amano; Masato Nakamura; Yuji Ikari
Journal:  J Clin Med       Date:  2020-11-10       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.